Inhibikase Therapeutics, Inc. Common Stock (IKT) Stock
Fundamentals
Recent news

New Strong Buy Stocks for February 13th
New Strong Buy Stocks for February 13th
IKT

New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 8th
IKT

Best Momentum Stocks to Buy for January 26th
Best Momentum Stocks to Buy for January 26th
IKT

New Strong Buy Stocks for January 26th
New Strong Buy Stocks for January 26th
IKT
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 4 articles
published over the past 14 days
Latest news

New Strong Buy Stocks for February 13th
New Strong Buy Stocks for February 13th
IKT

New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 8th
IKT

Best Momentum Stocks to Buy for January 26th
Best Momentum Stocks to Buy for January 26th
IKT

New Strong Buy Stocks for January 26th
New Strong Buy Stocks for January 26th
IKT
About Inhibikase Therapeutics, Inc. Common Stock
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark T. Iwicki | CEO & Director | 1966 |
| Dr. Christopher H. Cabell FACC, M.D. | President, Head of Research & Development and Chief Medical Officer | 1969 |
| Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A. | Chief Financial Officer | 1970 |
| Dr. John Adams Ph.D. | Chief Scientific Officer | — |
| Mr. Jeffrey J. Kagy | Chief Human Resources Officer | — |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Development Operations | — |
| Mr. Timothy J. Pigot | Chief Commercial & Strategy Officer | 1971 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +17.8 | -13.0 | +4.4 | -8.4 | +18.7 | +12.4 | +4.5 | -13.4 |



